Evaluation of prognostic value of vascular endothelial growth factor and endocan in non-small cell lung cancer
VEGF can serve as a potential biomarker for screening and prognostic assessment in early-stage NSCLC. In contrast, endocan did not demonstrate utility for such clinical purposes. VEGF may also be considered for the evaluation of treatment efficacy following surgical intervention.
Authors
- ZEYNEP SARIBAŞ
- ULAŞ KUMBASAR
- BURCU ANCIN
- SERKAN UYSAL
- ERKAN DİKMEN
- YİĞİT YILMAZ
- RIZA DOĞAN
- MESUT MELİH ÖZERCAN
- AHMET MÜDERRİSOĞLU
Institutions
- Hacettepe University (TR)
Publication Details
- Journal
- TURKISH JOURNAL OF MEDICAL SCIENCES
- Published
- 2025-12-12
- DOI
- https://doi.org/10.55730/1300-0144.6100
- Primary Topic
- Inflammation biomarkers and pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00